CommercialCoverageLow impact
08.02.13a, Delandistrogene moxeparvovec (delandistrogene moxeparvovec-rokl; Elevidys®)
Independence Blue Cross·Neurology, Pediatrics·Pharmacy
Effective date
Oct 29, 2025
We identified it
Jun 19, 2026
Summary
Insurance policy for Delandistrogene moxeparvovec (Elevidys®), a gene therapy for Duchenne muscular dystrophy, has been reissued with an effective date of October 29, 2025. This is a very recent commercial plan policy update that may affect coverage and billing requirements for this specialized pharmaceutical treatment.
Action Required
By October 29, 2025: Review updated commercial plan coverage policy for Elevidys® gene therapy. Billing team should verify current prior authorization requirements and coverage criteria for Delandistrogene moxeparvovec before submitting claims. Contact payer to confirm any changes to billing procedures for this specialized treatment.